Compass pathways stock forecast.
Based on the most recent data, CMPS has returned 5% so far this year. Meanwhile, stocks in the Medical group have lost about 16.7% on average. This means that COMPASS Pathways PLC Sponsored ADR is ...
Description. Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways …Financial highlights. Net loss for the three months ended 31 March 2023 was $24.2 million, or $0.57 loss per share (including non-cash share-based compensation expense of $4.1 million), compared with $21.2 million or $0.50 loss per share, during the same period in 2022 (including non-cash-share-based compensation expense of $3.1 million).WebSee the latest Compass Pathways PLC ADR stock price (CMPS:XNAS), related news, valuation, dividends and more to help you make your investing decisions.AnaptysBio presently has a consensus target price of $29.00, suggesting a potential upside of 105.09%. COMPASS Pathways has a consensus target price of $46.83, suggesting a potential upside of 683.17%. Given AnaptysBio's stronger consensus rating and higher probable upside, analysts plainly believe COMPASS Pathways is more …4 brokers have issued 1-year price targets for Atai Life Sciences' stock. Their ATAI share price targets range from $9.00 to $20.00. On average, they expect the company's stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 1,063.6% from the stock's current price.
Real time Compass Pathways Plc (CMPS) stock price quote, stock graph, news & analysis. What this means: InvestorsObserver gives Compass Pathways Plc ADR (CMPS) an overall rank of 34, which is below average. Compass Pathways Plc ADR is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 34 means that 66% of stocks appear more favorable to our system.
Compass Pathways has also returned positive data from a Phase 2 trial of its psilocybin formulation, using a similar "monitored sessions" approach, even providing music, soft furnishings and a ...
US20451W1018. Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and …A high-level overview of COMPASS Pathways plc (CMPS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.The latest price target for Compass Pathways ( NASDAQ: CMPS) was reported by Cantor Fitzgerald on Tuesday, August 22, 2023. The analyst firm set a price target for 21.00 expecting CMPS to rise to ...WebFresh off IPO, Compass sees mushrooming opportunity in psilocybin....CMPS Psychedelic company Compass Pathways PLC (CMPS) got off to a stellar start of trading on Friday, as investors hungry for the next new thing bought up shares. The U.K....
How to buy COMPASS Pathways PLC stock on Stash. 1. Enter the amount you'd like to invest in COMPASS Pathways PLC stock, then proceed to checkout. Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.
It may have a tough pill to swallow, but I'm still optimistic about psilocybin in general, and especially Cybin....CMPS At the time of publication, Tim Collins was long CYBN. Look how quickly we got bulled up. Let's check sentiment, the...
Stock Price Forecast. The 9 analysts offering 12-month price forecasts for Compass Inc have a median target of 2.70, with a high estimate of 5.00 and a low estimate of 2.00. The median estimate ... Psychedelics biotech giant COMPASS Pathways (NASDAQ: CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select ...WebOverall, the consensus among analysts is that Compass Pathways has a promising future ahead. CMPS Stock Analysis: Fluctuating Prices and Negative Earnings Growth, but Positive Forecast for the Future. On May 11, 2023, CMPS stock opened at the same price as the previous close, which was 8.59. Throughout the day, the stock’s price fluctuated ...Low. $35.00. Average. $71.83. Current Price. $60.31. Overview. Research & Ratings. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume ...Compass Pathways : ... However, the expert forecasts the stock moving up to $25, implying 252% upside potential. If so, FAT would easily be one of the sin stocks to buy.Oct 30, 2023 · Nikkei 225. 30,696.96. -0.95%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Compass Pathways PLC (CMPS.OQ) real-time stock quotes, news, price and financial information from ... Nov 9, 2021 · What happened. Compass Pathways ( CMPS 6.61%) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40. ...
Dec 1, 2023 · 8 Wall Street research analysts have issued 1-year target prices for Compass' shares. Their COMP share price targets range from $2.25 to $5.00. On average, they expect the company's stock price to reach $3.39 in the next twelve months. This suggests a possible upside of 47.2% from the stock's current price. COMPASS Pathways has a market cap of $299.3 million, and a 52-week range of $6.74 to $49.52. The stock has a price/book ratio of 1.32, and a price-to-free-cash-flow ratio of -6.9.WebDec 2, 2023 · The stock spiked 2.01% in intraday trading to $6.10 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is -5.43%, and it has moved by 5.54% in 30 days. Based on these gigs, the overall price performance for the year is -40.78%. The short interest in Compass Pathways Plc ADR (NASDAQ:CMPS) is 3.91 million shares ... Stock Price Forecast. The 5 analysts offering 12-month price forecasts for Compass Pathways PLC have a median target of 38.00, with a high estimate of 120.00 and a low estimate of 22.00. The median estimate represents a +488.24% increase from the last price of 6.46.From this work, Compass Pathways in my opinion is trading at around its current market price. Figure 6: Valuation of Compass Pathways (Source: Author's valuation work, using base data from CMPS' 10-K)
From this work, Compass Pathways in my opinion is trading at around its current market price. Figure 6: Valuation of Compass Pathways (Source: Author's valuation work, using base data from CMPS' 10-K)
Find the latest COMPASS Pathways Plc - American CMPS analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating ...WebWith its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences ( ATAI 1.87%) is having a rough go of things lately ...It is one of the best psychedelic stocks to invest in. On December 15, EF Hutton analyst Elemer Piros initiated coverage of COMPASS Pathways plc (NASDAQ:CMPS) with a Buy rating and a $38 price target.One reason why now's a decent time to buy psychedelics stocks is that there's an ongoing fire sale across the entire industry, thanks to the bear market. Leaders like COMPASS Pathways ( CMPS 3.22% ...COMPASS Pathways PLC (CMPS) stock is down -1.77% while the S&P 500 is higher by 1.89% as of 2:59 PM on Thursday, Apr 27. CMPS has fallen -$0.15 from the previous closing price of $8.17 on volume of 236,713 shares. Over the past year the S&P 500 has fallen -1.22% while CMPS has fallen -21.27%. CMPS lost -$0.01 per share the …Canaccord Genuity analyst Sumant Kulkarni gives the biotech company an $80 price target....CMPS Compass Pathways (CMPS) has grabbed the interest of Canaccord Genuity analyst Sumant Kulkarni, who gave the biotech company an $80 price target....Hedge funds don't have many shares in COMPASS Pathways. Our data shows that Atai Life Sciences N.V. is the largest shareholder with 23% of shares outstanding.Discover historical prices for CMPS stock on Yahoo Finance. View daily, weekly or monthly format back to when COMPASS Pathways plc stock was issued.
The financials. The average price target from the nine analysts following COMPASS pathways is $68 against a current price of $14.9, implying a 356% upside and a target market cap of $3 billion. I ...
1 de jul. de 2023 ... While Compass Pathways' (CMPS 2.17%) stock is near $8, the analysts on Wall Street are figuring, on average, that its shares will explode by ...
For Compass Pathways, ( CMPS 2.01%) whose COMP360 program aims to address treatment-resistant depression (TRD) with a combination of psilocybin and clinician-led psychological support, that's ...Find the latest COMPASS Pathways Plc - American CMPS analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating ...WebWe are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. News & events. News releases. SEC filings & annual reports. Our annual review. Stock information. Stock quote & chart. Historical price lookup. Corporate governance.Web17 de out. de 2022 ... Math over Myth is your weekly source for psychedelic stock updates, including Compass Pathways and Revive Therapeutics.Discover COMPASS Pathways' earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers.... Stock Price Chart Interactive Chart > · Price chart for CMPS. COMPASS Pathways PLC ADR (CMPS) Company Bio. COMPASS Pathways plc operates as a mental health care ...In the same quarter last year, COMPASS Pathways's earnings per share (EPS) was -$0.44. COMPASS Pathways is expected to release next earnings on 02/26/2024, with ...47.29. -1.64%. 4.73M. Find the latest Compass Pathways Plc (CMPS) stock forecast, 12-month price target, predictions and analyst recommendations.WebMarket Activity. Funds + ETFs. Analyst ratings can be used in addition to other personal research work prior to making investment decisions. Do Not Sell My Personal Information (CA Residents Only ...Dec 1, 2023 · CMPS Earnings Date and Information. COMPASS Pathways last posted its quarterly earnings results on November 2nd, 2023. The reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.17. COMPASS Pathways has generated ($2.59) earnings per share over the last year ( ($2.59) diluted earnings per share).
A high-level overview of COMPASS Pathways plc (CMPS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Latest CMPS News. View. COMPASS Pathways (CMPS, $5.98) entered Downtrend as Momentum indicator drops below 0 level on Nov 30, 2023. Tickeron - Stocks • 3 days ago. Compass Pathways to participate in upcoming Evercore investor conference. Globe Newswire • 10 days ago.WebNov 30, 2023 · Overview Financials Statistics Forecast Profile Chart Forecast Analyst Ratings COMPASS Pathways Stock Forecast All Analysts Top Analysts Stock Price Forecast According to 5 stock analysts, the average 12-month stock price forecast for CMPS stock stock is $49.6, which predicts an increase of 722.55%. The lowest target is $19 and the highest is $120. Instagram:https://instagram. stock arryark fintech innovation etfvrtx stock priceznog stocks Mar 2, 2022 · COMP360 Overview (August Company Presentation) Psilocybin is a hallucinogenic chemical found in psychedelic mushrooms. It also is in Phase II clinical trials for the treatment of post-traumatic ... Discover the reasons why Compass Pathways Plc (CMPS) stock is experiencing a decline today. Our expert analysis provides insights into the factors driving this market movement and what it means for Compass Pathways Plc investors. Stay up-to-date with the latest financial news and trends with Stockscan! stock market tuesdaylincoln penny 2009 Despite having an IPO just three months ago, Compass Pathways (NASDAQ: CMPS) is already up a staggering 224% from its IPO price of $17. If you invested $10,000 in its first-ever public offering ...Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression, and launches new research center. Read more. Compass is a biotechnology company dedicated to accelerating patient access and experience to evidence-based innovation in mental health care. liberty one dollar coin 1979 See COMPASS Pathways plc (CMPS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. May 6, 2023 · On May 2, COMPASS Pathways (CMPS 6.61%) announced that the American Medical Association (AMA) has given the green light for three new current procedural terminology (CPT) codes for psychedelic ... 13 มี.ค. 2566 ... Analysts at Canaccord Genuity (TSX:CF, LSE:CF) have reiterated their 'Buy' rating and US$60 price target for COMPASS Pathways after the ...